Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Recent & Breaking News (NDAQ:AVXL)

Digital-Based Markets Ramp Up in 2015, Lead By Under-the-Radar Gems

Accesswire August 25, 2015

Micro-Cap Investing Reaches New Highs; Blazing a Trail in Surging Markets Like Mobile Gaming, Energy, and Life Sciences

Accesswire August 20, 2015

Anavex Reports Fiscal Third Quarter 2015 Financial Results

GlobeNewswire August 17, 2015

Anavex Receives Notice of Allowance for U.S. Patent Application Related to ANAVEX 2-73

GlobeNewswire August 12, 2015

Anavex Awarded Grant From The Michael J. Fox Foundation for Parkinson's Research

GlobeNewswire August 10, 2015

Anavex Presents Positive Initial Phase 2a Study Data With ANAVEX 2-73 Showing Early Evidence of Improving Cognition in Patients With Alzheimer's Disease at AAIC 2015

GlobeNewswire July 22, 2015

Anavex to Present Initial Clinical Data From the Phase 2a Clinical Trial of ANAVEX 2-73 at the Alzheimer's Association International Conference (AAIC)

GlobeNewswire June 30, 2015

Anavex Strengthens Board of Directors

GlobeNewswire June 18, 2015

Anavex Encouraged by Data Showing Sigma-1 Receptor Reduces Tau Dysfunction, a Hallmark of Alzheimer's Disease

GlobeNewswire May 21, 2015

Anavex Releases Promising Full Preclinical Epilepsy Data at Antiepileptic Drug Trials XIII Conference

GlobeNewswire May 18, 2015

Anavex Reports Fiscal Second Quarter 2015 Financial Results

GlobeNewswire May 15, 2015

Anavex to Present at 2015 Marcum Conference on May 27th

GlobeNewswire May 13, 2015

Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference

GlobeNewswire April 23, 2015

Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain Injuries

GlobeNewswire April 7, 2015

Anavex Presents Positive Results for Both ANAVEX 2-73 and ANAVEX 3-71 in Alzheimer's Models at 2015 AD/PD(TM) Conference

GlobeNewswire March 23, 2015

New Data on Two Anavex Alzheimer's Drugs to be Unveiled at AD/PD 2015

GlobeNewswire March 19, 2015

Anavex to Participate in Phase 3 Clinical Trials Panel at AD/PD 2015

GlobeNewswire March 17, 2015

Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory Board

GlobeNewswire March 12, 2015

Anavex to Present at Sigma-1 Receptors Symposium

GlobeNewswire March 10, 2015

Anavex Appoints Scientific Advisory Board Member With Expertise in Protein Misfolding Neurodegenerative Diseases

GlobeNewswire March 5, 2015